Your browser doesn't support javascript.
Y380Q novel mutation in receptor-binding domain of SARS-CoV-2 spike protein together with C379W interfere in the neutralizing antibodies interaction.
Sartor, Ivaine Tais Sauthier; Varela, Fernanda Hammes; Meireles, Mariana Rost; Kern, Luciane Beatriz; Azevedo, Thaís Raupp; Giannini, Gabriela Luchiari Tumioto; da Silva, Mariana Soares; Demoliner, Meriane; Gularte, Juliana Schons; de Almeida, Paula Rodrigues; Fleck, Juliane Deise; Zavaglia, Gabriela Oliveira; Fernandes, Ingrid Rodrigues; de David, Caroline Nespolo; Santos, Amanda Paz; de Almeida, Walquiria Aparecida Ferreira; Porto, Victor Bertollo Gomes; Scotta, Marcelo Comerlato; Vieira, Gustavo Fioravanti; Spilki, Fernando Rosado; Stein, Renato T; Polese-Bonatto, Márcia.
  • Sartor ITS; Social Responsibility, Hospital Moinhos de Vento, Porto Alegre, Brazil. Electronic address: ivaine.sartor@hmv.org.br.
  • Varela FH; Social Responsibility, Hospital Moinhos de Vento, Porto Alegre, Brazil; School of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil. Electronic address: fernanda.varela@hmv.org.br.
  • Meireles MR; Genetics Department, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
  • Kern LB; Social Responsibility, Hospital Moinhos de Vento, Porto Alegre, Brazil.
  • Azevedo TR; Social Responsibility, Hospital Moinhos de Vento, Porto Alegre, Brazil.
  • Giannini GLT; Laboratory of Genetics and Molecular Biology, Hospital Moinhos de Vento, Porto Alegre, Brazil.
  • da Silva MS; Laboratory of Molecular Microbiology, Universidade FEEVALE, Novo Hamburgo, Brazil.
  • Demoliner M; Laboratory of Molecular Microbiology, Universidade FEEVALE, Novo Hamburgo, Brazil.
  • Gularte JS; Laboratory of Molecular Microbiology, Universidade FEEVALE, Novo Hamburgo, Brazil.
  • de Almeida PR; Laboratory of Molecular Microbiology, Universidade FEEVALE, Novo Hamburgo, Brazil.
  • Fleck JD; Laboratory of Molecular Microbiology, Universidade FEEVALE, Novo Hamburgo, Brazil.
  • Zavaglia GO; Social Responsibility, Hospital Moinhos de Vento, Porto Alegre, Brazil.
  • Fernandes IR; Social Responsibility, Hospital Moinhos de Vento, Porto Alegre, Brazil.
  • de David CN; Social Responsibility, Hospital Moinhos de Vento, Porto Alegre, Brazil.
  • Santos AP; Social Responsibility, Hospital Moinhos de Vento, Porto Alegre, Brazil.
  • de Almeida WAF; General Coordination, National Immunization Program, Brazilian Ministry of Health, Brasilia, Brazil.
  • Porto VBG; General Coordination, National Immunization Program, Brazilian Ministry of Health, Brasilia, Brazil.
  • Scotta MC; Social Responsibility, Hospital Moinhos de Vento, Porto Alegre, Brazil; School of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.
  • Vieira GF; Genetics Department, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil; Post-Graduation Program in Health and Human Development, Universidade La Salle, Canoas, Brazil.
  • Spilki FR; Laboratory of Molecular Microbiology, Universidade FEEVALE, Novo Hamburgo, Brazil.
  • Stein RT; Social Responsibility, Hospital Moinhos de Vento, Porto Alegre, Brazil; School of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.
  • Polese-Bonatto M; Social Responsibility, Hospital Moinhos de Vento, Porto Alegre, Brazil. Electronic address: marcia.bonatto@hmv.org.br.
Diagn Microbiol Infect Dis ; 102(4): 115636, 2022 Apr.
Article in English | MEDLINE | ID: covidwho-1637337
ABSTRACT
We aimed to describe the SARS-CoV-2 lineages circulating early pandemic among samples with S gene dropout and characterize the receptor-binding domain (RBD) of viral spike protein. Adults and children older than 2 months with signs and symptoms of COVID-19 were prospectively enrolled from May to October in Porto Alegre, Brazil. All participants performed RT-PCR assay, and samples with S gene dropout and cycle threshold < 30 were submitted to high-throughput sequencing (HTS). 484 out of 1,557 participants tested positive for SARS-CoV-2. The S gene dropout was detected in 7.4% (36/484) and a peak was observed in August. The B.1.1.28, B.1.91 and B.1.1.33 lineages were circulating in early pandemic. The RBD novel mutation (Y380Q) was found in one sample occurring simultaneously with C379W and V395A, and the B.1.91 lineage in the spike protein. The Y380Q and C379W may interfere with the binding of neutralizing antibodies (CR3022, EY6A, H014, S304).
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / COVID-19 Limits: Child / Humans / Infant Language: English Journal: Diagn Microbiol Infect Dis Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / COVID-19 Limits: Child / Humans / Infant Language: English Journal: Diagn Microbiol Infect Dis Year: 2022 Document Type: Article